Halotestin and MK-2866 Interaction

Avoid
Mechanism-based 64% confidence

Halotestin and MK-2866 have a potentially harmful interaction with 64% confidence. Both Halotestin and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

Halotestin

Oral Anabolic Steroid | Extreme Strength & Aggression

Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue.

Half-life: ~9.5 hours Typical dose: 10-20 mg/day anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskhepatotoxic
View full profile

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate

Shared Safety Flags

2x 2 androgenic compounds (Halotestin, MK-2866). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the carcinogenic-risk safety flag (Halotestin, MK-2866). Monitor accordingly.
2x 2 hepatotoxic compounds (Halotestin, MK-2866). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (Halotestin, MK-2866). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Halotestin, MK-2866). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take Halotestin with MK-2866?

Combining Halotestin with MK-2866 is not recommended. Both Halotestin and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Halotestin and MK-2866 safe together?

This combination carries significant risk. Both Halotestin and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Halotestin and MK-2866?

Both Halotestin and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Halotestin and MK-2866?

Halotestin has a half-life of ~9.5 hours and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Halotestin vs MK-2866

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.